886755-45-9

Upstream product

• 1018788-84-5 4-(1H-indazol-3-yl)benzoic acid 
• 64-17-5 ethanol 
• 746651-78-5 ethyl 4-(2-bromobenzoyl)benzoate 
• 67104-64-7 2-bromophenyl(4-methylphenyl)methanone 
• 59142-66-4 (2-bromophenyl)(p-tolyl)methanol 
• 106-38-7 para-bromotoluene 
• 6630-33-7 ortho-bromobenzaldehyde 
• 1001084-41-8 3-(4-methoxycarbonylphenyl)indazole 

Downstream Products

• 1018789-01-9 C₁₉H₂₀N₂O₂ 
• 1018789-02-0 C₂₀H₂₂N₂O₂ 
• 1018788-96-9 C₂₂H₁₉N₃O₂ 
• 1018788-94-7 C₂₂H₁₉N₃O₂ 
• 886755-47-1 N-2-benzyl-3-(4-ethoxycarbonylphenyl)indazole 
• 170632-41-4 1-benzyl-3-(4'-ethoxycarbonylphenyl)indazole 
• 1001084-49-6 N-1-(4-chlorobenzyl)-3-(4-ethoxycarbonylphenyl)indazole 
• 886755-50-6 ethyl 4-[1-(2-fluorobenzyl)-1H-indazol-3-yl]benzoate 
• 1001084-45-2 N-1-(2-chlorobenzyl)-3-(4-ethoxycarbonylphenyl)indazole 
• 1018788-91-4 C₂₄H₂₂N₂O₃ 
• 1018788-99-2 C₁₈H₁₈N₂O₂ 
• 1018789-00-8 C₁₉H₂₀N₂O₂ 
• 1018788-93-6 C₂₄H₂₂N₂O₃ 
• 1018788-92-5 C₂₄H₂₂N₂O₃ 

Relevant academic research and scientific papers

Preparation method of indazole and application of indazole in medicine synthesis

The invention belongs to the field of chemicals, and relates to a preparation method of indazole and an application of the indazole in medicine synthesis. The invention discloses a preparation method of indazole and an application of the indazole in synthesizing 1H-indazole-3-carboxylic acid, lonidamine, a compound 8, a compound 9, a compound 10, axitinib, YD-3, YC-1 and similar substances thereof.

Copper(I) Oxide-Mediated Cyclization of o-Haloaryl N-Tosylhydrazones: Efficient Synthesis of Indazoles

An efficient synthesis of indazoles from readily accessible E/Z mixtures of o-haloaryl N-tosylhydrazones has been developed. The thermo-induced isomerization of N-tosylhydrazones is discussed. A series of valuable indazole derivatives are prepared in good yields, and the method has been successfully applied to the synthesis of the bioactive compounds, lonidamine, AF-2785, axitinib, YC-1 and YD-3.

Synthesis and antiplatelet activity of ethyl 4-(1-benzyl-1H-indazol-3-yl)benzoate (YD-3) derivatives

Previously, ethyl 4-(1-benzyl-1H-indazol-3-yl)benzoate (YD-3) was identified by us as the first non-peptide protease-activated receptor 4 (PAR4) antagonist. To continue on our development of novel anti-PAR4 agents, YD-3 was used as a lead compound and a series of its derivatives were synthesized and evaluated for their selective anti-PAR4 activity. Through structure-activity relationship (SAR) study, we identified the important functional groups contributing to anti-PAR4 activity, and these functional groups were kept intact during subsequent structural modification. Several new compounds with anti-PAR4 activity comparable to YD-3 were identified. Among them, ethyl 4-[1-(3-chlorobenzyl)-1H-indazol-3-yl]benzoate (33) showed the most potent inhibitory effect on PAR4-mediated platelet aggregation, ATP release, and P-selectin expression. On the other hand, ethyl 4-(1-phenyl-1H-indazol-3-yl)benzoate (83) exhibited dual inhibitory effects on PAR4 and thromboxane formation from arachidonic acid. The above findings can be used as guidelines for development of novel antiplatelet drug candidates.

Microwave-assisted synthesis of N-2-benzyl-3-(4-ethoxycarbonylphenyl)indazole derivatives

The microwave-assisted synthesis for promoting N-2 substituted indazoles as the major products were successfully developed by treating 3-(4-ethoxycarbonylphenyl)indazoles with various substituted benzyl chloride (benzyl, o-chlorobenzyl, m-chlorobenzyl, an

Synthesis of N2 - (substituted arylmethyl) -3- (substituted phenyl) indazoles as novel anti-angiogenic agents

Novel compounds of 2-(substituted arylmethyl)-3-(substituted phenyl)-2H-indazoles and 1-(substituted arylmethyl)-3-(substituted phenyl)-1H-indazoles are synthesized, and useful as anti-angiogenic agents.